Sa1862 FERTILITY RATE IN WOMEN WITN INFLAMMATORY BOWEL DISEASE IS DECREASED COMPARED TO GENERAL POPULATION: FISRT MULTICENTRE SURVEY IN THE CZECH REPUBLIC

Background: Several previous studies reported the negative impact of inflammatory bowel disease (IBD) on reproductive plans and fertility rate. The aim of our study was to investigate, for the first time, reproductive attitudes and fertility rate among Czech patients with IBD. Methods: Between March and August 2019, consecutive patients with IBD from 22 centres across the Czech Republic responded anonymously to a predefined questionnaire focused on the patients’ demographics, details of IBD and treatment, gynaecological/urological history, reproductive issues and patients’ knowledge on this topic. Results: The questionnaire was filled in by 798 patients (526 women; median age 34 years, 66% with Crohn’s disease). Of these, 58% of the females and 47.1% of the males already had ≥ 1 child (median 2 children). Women with IBD were significantly more worried about infertility (55.5% versus 22.4%), had more limitations in their sexual life (53.2% vs. 26.8%) and more frequently changed their earlier reproductive plans (27.6% versus 11.0%) than the males (p < 0.0001). The total fertility rate in female IBD patients was lower compared to the general population with 1.004 live births/IBD woman versus 1.69 live births/woman in the Czech population. The pattern of decreased fertility was observed in all age-specific categories. Of the childless patients, 14% of the women and 18.1% of the men were voluntarily childless. Approximately one-half of them indicated their IBD to be the primary cause. Conclusions: IBD seems to have a negative impact on patients’ reproductive plans and attitudes. The fertility rate in Czech IBD female patients was decreased compared to the general population in this study.

Download Full-text

The use of vedolizumab for the treatment of inflammatory bowel disease patients in the Czech Republic

Gastroenterologie a hepatologie ◽

10.14735/amgh201719 ◽

2017 ◽

Vol 71 (1) ◽

pp. 19-23

Author(s):

Přemysl Falt

Keyword(s):

Inflammatory Bowel Disease ◽

Czech Republic ◽

Bowel Disease ◽

The Czech Republic ◽

Inflammatory Bowel

Download Full-text

Incidence of Crohn Disease in the Czech Republic in the Years 1990 to 2001 and Assessment of Pediatric Population with Inflammatory Bowel Disease

Journal of Pediatric Gastroenterology and Nutrition ◽

10.1097/01.mpg.0000189328.47150.bc ◽

2006 ◽

Vol 42 (2) ◽

pp. 186-189 ◽

Cited By ~ 48

Author(s):

Oldrich Pozler ◽

Jan Maly ◽

Oldriska Bonova ◽

Petr Dedek ◽

Pavel Fr??hauf ◽

...

Keyword(s):

Inflammatory Bowel Disease ◽

Czech Republic ◽

Crohn Disease ◽

Bowel Disease ◽

Pediatric Population ◽

The Czech Republic ◽

Inflammatory Bowel

Download Full-text

A Systematic Review and Meta-analysis of Paediatric Inflammatory Bowel Disease Incidence and Prevalence Across Europe

Journal of Crohn s and Colitis ◽

10.1093/ecco-jcc/jjaa037 ◽

2020 ◽

Vol 14 (8) ◽

pp. 1119-1148 ◽

Cited By ~ 7

Author(s):

S E Roberts ◽

K Thorne ◽

N Thapar ◽

I Broekaert ◽

M A Benninga ◽

...

Keyword(s):

Systematic Review ◽

Inflammatory Bowel Disease ◽

Czech Republic ◽

Bowel Disease ◽

Meta Analysis ◽

Grey Literature ◽

Incidence Rates ◽

Cochrane Library ◽

The Czech Republic ◽

Inflammatory Bowel

Abstract Background and Aims Inflammatory bowel disease [IBD] is often one of the most devastating and debilitating chronic gastrointestinal disorders in children and adolescents. The main objectives here were to systematically review the incidence and prevalence of paediatric IBD across all 51 European states. Methods We undertook a systematic review and meta-analysis based on PubMed, CINAHL, the Cochrane Library, searches of reference lists, grey literature and websites, covering the period from 1970 to 2018. Results Incidence rates for both paediatric Crohn’s disease [CD] and ulcerative colitis [UC] were higher in northern Europe than in other European regions. There have been large increases in the incidence of both paediatric CD and UC over the last 50 years, which appear widespread across Europe. The largest increases for CD have been reported from Sweden, Wales, England, the Czech Republic, Denmark and Hungary, and for UC from the Czech Republic, Ireland, Sweden and Hungary. Incidence rates for paediatric CD have increased up to 9 or 10 per 100 000 population in parts of Europe, including Scandinavia, while rates for paediatric UC are often slightly lower than for CD. Prevalence reported for CD ranged from 8.2 per 100 000 to approximately 60 and, for UC, from 8.3 to approximately 30. Conclusions The incidence of paediatric IBD continues to increase throughout Europe. There is stronger evidence of a north–south than an east–west gradient in incidence across Europe. Further prospective studies are needed, preferably multinational and based on IBD registries, using standardized definitions, methodology and timescales.

Download Full-text

Sa1852 VEDOLIZUMAB DRUG LEVELS IN MATERNAL AND CORD BLOOD FOLLOWING TREATMENT OF INFLAMMATORY BOWEL DISEASE IN PREGNANCY: ONGOING MULTICENTRE PROSPECTIVE STUDY FROM THE CZECH REPUBLIC

Gastroenterology ◽

10.1016/s0016-5085(20)31811-4 ◽

2020 ◽

Vol 158 (6) ◽

pp. S-451 ◽

Cited By ~ 1

Author(s):

Barbora Pipek ◽

Dana Duricova ◽

Katarina Mitrova ◽

Martin Bortlik ◽

ondrej urban ◽

...

Keyword(s):

Inflammatory Bowel Disease ◽

Czech Republic ◽

Prospective Study ◽

Cord Blood ◽

Bowel Disease ◽

The Czech Republic ◽

Drug Levels ◽

Inflammatory Bowel ◽

Multicentre Prospective Study ◽

In Pregnancy

Download Full-text

The Incidence of Inflammatory Bowel Disease Is Increasing Among Children 15 Years Old and Younger in the Czech Republic

Journal of Pediatric Gastroenterology and Nutrition ◽

10.1097/00005176-200403000-00028 ◽

2004 ◽

Vol 38 (3) ◽

pp. 362-363 ◽

Cited By ~ 21

Author(s):

Antonín Kolek ◽

Vladimír Janout ◽

Martin Tichý ◽

Michal Grepl

Keyword(s):

Inflammatory Bowel Disease ◽

Czech Republic ◽

Bowel Disease ◽

The Czech Republic ◽

Inflammatory Bowel

Download Full-text

Risk and outcomes of coronavirus disease (COVID-19) in patients with inflammatory bowel disease: a systematic review and meta-analysis

United European Gastroenterology Journal ◽

10.1177/2050640620972602 ◽

2020 ◽

pp. 205064062097260

Author(s):

Anupam Kumar Singh ◽

Anuraag Jena ◽

Praveen Kumar-M ◽

Vishal Sharma ◽

Shaji Sebastian

Keyword(s):

Ulcerative Colitis ◽

Intensive Care Unit ◽

Inflammatory Bowel Disease ◽

Intensive Care ◽

Crohn’S Disease ◽

Crohn's Disease ◽

General Population ◽

Bowel Disease ◽

Intensive Care Unit Care ◽

Inflammatory Bowel

Background The risk of severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) infection and clinical outcomes of coronavirus disease (COVID-19) in inflammatory bowel disease are unclear. Methods We searched PubMed and Embase with the keywords: inflammatory bowel disease, Crohn’s disease, ulcerative colitis and COVID-19, novel coronavirus and SARS-CoV-2. We included studies reporting the frequency of COVID-19 infection and outcomes (hospitalisation, need for intensive care unit care and mortality) in patients with inflammatory bowel disease. We estimated the pooled incidence of COVID-19 in inflammatory bowel disease and comparative risk vis-a-vis the general population. We also estimated the pooled frequency of outcomes and compared them in patients who received and did not receive drugs for inflammatory bowel disease. Results Twenty-four studies were included. The pooled incidence rate of COVID-19 per 1000 patients of inflammatory bowel disease and the general population were 4.02 (95% confidence interval (CI) 1.44–11.17) and 6.59 (3.25–13.35), respectively, with no increase in relative risk (0.47, 0.18–1.26) in inflammatory bowel disease. The relative risk of the acquisition of COVID-19 was not different between ulcerative colitis and Crohn’s disease (1.03, 0.62–1.71). The pooled proportion of COVID-19-positive inflammatory bowel disease patients requiring hospitalisation and intensive care unit care was 27.29% and 5.33% while pooled mortality was 4.27%. The risk of adverse outcomes was higher in ulcerative colitis compared to Crohn’s disease. The relative risks of hospitalisation, intensive care unit admission and mortality were lower for patients on biological agents (0.34, 0.19–0.61; 0.49, 0.33–0.72 and 0.22, 0.13–0.38, respectively) but higher with steroids (1.99, 1.64–2.40; 3.41, 2.28–5.11 and 2.70, 1.61–4.55) or 5-aminosalicylate (1.59, 1.39–1.82; 2.38, 1.26–4.48 and 2.62, 1.67–4.11) use. Conclusion SARS-CoV-2 infection risk in patients with inflammatory bowel disease is comparable to the general population. Outcomes of COVID-19-positive inflammatory bowel disease patients are worse in ulcerative colitis, those on steroids or 5-aminosalicylates but outcomes are better with biological agents.

Download Full-text

Insurance Rating of Patients with Inflammatory Bowel Disease: Report of a Conference on Morbidity and Mortality

Canadian Journal of Gastroenterology ◽

10.1155/1994/319149 ◽

1994 ◽

Vol 8 (7) ◽

pp. 438-445 ◽

Cited By ~ 4

Author(s):

Ivan T Beck ◽

Desmond J Leddin ◽

Suzanne E Lemire ◽

Eldon A Shaffer ◽

Lloyd R Sutherland ◽

...

Keyword(s):

Inflammatory Bowel Disease ◽

General Population ◽

Bowel Disease ◽

Medical Officer ◽

Morbidity And Mortality ◽

Insurance Company ◽

Recent Edition ◽

Close Cooperation ◽

Inflammatory Bowel

Patient members reported to the Crohn’s and Colitis Foundation of Canada (CCFC) about their difficulties to obtain insurance. In 1991, the Lay Board of the CCFC requested its Medical Advisory Board (MAB) to investigate this problem. At that time, insurance ratings could be illustrated by the 1985 edition of Brackenridge’s monograph on life risks. The MAB found that data on mortality were outdated. A conference on morbidity and mortality of inflammatory bowel disease (IBD) was organized by the authors and held in May 1992. Based on questionnaires to patients, evidence provided by invited speakers and the results of small group conferences, it was concluded that patients with IBD have difficulties in obtaining insurance, even though the quality of life and mortality of IBD patients is not very different from that of the general population. However, the mortality rate of the healthy insured population is lower than that of the general population, and thus much lower than that of IBD patients. Patients have a better chance to obtain insurance if there is a close cooperation between the treating physician and the medical officer of the insurance company. Changes have occurred since the conference held in May 1992. The recent edition of Brackenridge’s text (1992) provides a better prognosis but unfortunately unchanged rating for patients with IBD than did the 1985 edition. Close cooperation between the Patient Advisory Committee of the CCFC and the Executives of the Canadian Life Insurance Medical Officers Association may further improve the insurance rating of patients with IBD.

Download Full-text

Risk of Anxiety and Depression in Patients with Inflammatory Bowel Disease: A Nationwide, Population-Based Study

Journal of Clinical Medicine ◽

10.3390/jcm8050654 ◽

2019 ◽

Vol 8 (5) ◽

pp. 654 ◽

Cited By ~ 17

Author(s):

Kookhwan Choi ◽

Jaeyoung Chun ◽

Kyungdo Han ◽

Seona Park ◽

Hosim Soh ◽

...

Keyword(s):

Inflammatory Bowel Disease ◽

General Population ◽

Bowel Disease ◽

Population Based ◽

Anxiety And Depression ◽

Healthcare Insurance ◽

Inflammatory Bowel ◽

One Year ◽

Constant Slope

Background and Aims: Inflammatory bowel disease (IBD) may be associated with anxiety and depression. The aim of this study was to evaluate the incidence of anxiety and depression in patients with IBD compared to the general population. Methods: A nationwide population-based cohort study was conducted using claims data from the National Healthcare Insurance service in Korea. We compared the incidence of anxiety and depression between 15,569 IBD patients and 46,707 non-IBD controls, age and sex matched at a ratio of 1:3. Results: During a mean follow-up of six years, IBD patients experienced significantly more anxiety (12.2% vs. 8.7%; p < 0.001) and depression (8.0% vs. 4.7%; p < 0.001) compared to controls. The curves showing cumulative incidences of anxiety and depression showed a steep rise within one year following a diagnosis of IBD, leading to lines with a constant slope. The hazard ratio (HR) for new onset anxiety following a diagnosis of Crohn’s disease (CD) and ulcerative colitis (UC) was 1.63 and 1.60, respectively, compared to controls (p < 0.001). Compared to controls, the HR for developing depression after a diagnosis of CD and UC was 2.09 and 2.00, respectively (p < 0.001). The risks of anxiety and depression in patients with IBD were higher compared to controls, except in those with diabetes mellitus, hypertension, and dyslipidemia, or who required immunomodulators and biologics within one year of the IBD diagnosis. Conclusions: The risk of anxiety and depression increased after a diagnosis of IBD compared to the general population.

Download Full-text